Metformin and parameters of physical health

Internal Medicine

Volumn 47, Issue 8, 2008, Pages 697-703

  Helvaci, Mehmet Rami ^a   Kaya, Hasan ^a   Borazan, Ali ^a   Ozer, Cahit ^a   Seyhanli, Mahmut ^b   Yalcin, Atilla ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

Excess weight; Fifty years of age; Metformin

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; WHITE COAT HYPERTENSION; AGE; CLINICAL TRIAL; COMPARATIVE STUDY; DIET THERAPY; DOSE RESPONSE; METABOLISM; MIDDLE AGED;

AGE FACTORS; AGED; BLOOD GLUCOSE; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OBESITY; PREVALENCE;

EID: 44649098532     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0787     Document Type: Article

References (32)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 17: 106: 3143-3421, 2002.
2. Helvaci MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. Int Heart J 48: 605-613, 2007.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003.
4. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25: 899-904, 2002.
5. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160, 2003.
6. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813-1818, 2001.
7. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92: 17-22, 2003.
8. Yudldn JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972-978, 1999.
9. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282: 2131-2135, 1999.
10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
11. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355: 763-778, 2006.
12. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 3: CD002966, 2005.
13. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333: 541-549, 1995.
14. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowing agent: a meta-analysis. Diabetes Metab Rev 11: 57-62, 1995.
15. Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13: 1-8, 1990.
16. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21: 821-848, 2003.
17. Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38: 202-206, 1999.
18. Zhou B, Wu Y, Yang J, Li Y, Zhang H, Zhao L. Overweight is an independent risk factor for cardiovascular disease in Chinese populations. Obes Rev 3: 147-156, 2002.
19. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases - report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci 15: 245-252, 2002.
20. Calle EE, Thun MJ, Petrelli IM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341: 1097-1105, 1999.
21. Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society! Intern Med 45: 671-674, 2006.
22. Hozawa A, Ohkubo T, Kikuya M, et al. Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 25: 57-63, 2002.
23. Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med 15: 348-357, 2004.
24. Helvaci MR, Kaya H, Seyhanli M, Cosar E. White coat hypertension is associated with a greater all-cause mortality. J Health Sci 53: 156-160, 2007.
25. Curgunlu A, Karter Y, Uzun H, et al. Hyperhomocysteinemia: an additional risk factor in white coat hypertension. Int Heart J 46: 245-254, 2005.
26. Nattrass M, Alberti KG. Biguanides. Diabetologia 14: 71-74, 1978.
27. Stumvoll M, Nutjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550-554, 1995.
28. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 36: 632-640, 1987.
29. Chang CT, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 15: 398-402, 2002.
30. Gore DC, Jahoor F, Hibbert JM, DeMaria EJ. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 224: 97-102, 1996.
31. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18: 779-784, 1995.
32. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 20: 377-384, 1999.